SBRA · Nasdaq
Sabra Health Care REIT, Inc.: financial statements
Financially weak · see the checkFigures in USD, fiscal years
Revenue and net income
Operating and free cash flow
Margins
Returns
Income statement
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Last year |
|---|---|---|---|---|---|---|---|
| Revenue | $599M | $570M | $625M | $648M | $703M | $775M | +10% |
| Operating income | $256M | $179M | $127M | $132M | $243M | $266M | +9% |
| EBITDA | $433M | $358M | $315M | $315M | $413M | $453M | +10% |
| Interest expense | $100M | $98.6M | $105M | $113M | $115M | $112M | -2% |
| Profit before tax | $156M | $80.7M | $21.7M | $18.7M | $128M | $153M | +20% |
| Income tax | $710K | $1.8M | $1.2M | $2.0M | $1.0M | $1.8M | +83% |
| Net income | $138M | -$113M | -$77.6M | $13.8M | $127M | $156M | +23% |
Cash flow
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Last year |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $355M | $356M | $316M | $301M | $311M | $349M | +12% |
| Free cash flow | $355M | $356M | $316M | $301M | $311M | $349M | +12% |
| Depreciation & amortization | $177M | $179M | $188M | $183M | $170M | $187M | +10% |
Balance sheet
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Last year |
|---|---|---|---|---|---|---|---|
| Cash | $59.1M | $112M | $49.3M | $41.3M | $60.5M | $71.5M | +18% |
| Total assets | $6.0B | $6.0B | $5.7B | $5.4B | $5.3B | $5.5B | +4% |
| Financial debt | $2.4B | $2.4B | $2.5B | $2.4B | $2.4B | $2.5B | +5% |
| Total liabilities | $2.6B | $2.6B | $2.7B | $2.6B | $2.6B | $2.7B | +4% |
| Shareholders' equity | $3.4B | $3.4B | $3.1B | $2.8B | $2.7B | $2.8B | +3% |
| Net debt | $2.3B | $2.3B | $2.5B | $2.4B | $2.4B | $2.5B | +4% |
Dividend profile
- Paying in a row
- 15+ years
- Raised in a row
- 0 years
- Growth per year
- -2.3%
- Paid out of profit
- 286.1%
- Paid out of free cash
- 88.3%
Latest dividend per share: 1.20 USD. Dividends exceeded profit over the last 3 years, which cannot last without borrowing or reserves. Without share prices EdgeScore shows no dividend yield.
Dividends
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Last year |
|---|---|---|---|---|---|---|---|
| Dividends paid | $278M | $263M | $277M | $277M | $280M | $289M | +3% |
| Dividend per share | 1.35 | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 | |
| Dividends / net income | 201.1% | — | — | 2016.9% | 221.1% | 186.0% | |
| Dividends / free cash flow | 78.4% | 73.8% | 87.8% | 92.3% | 90.2% | 83.0% |
Ratios
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Last year | |
|---|---|---|---|---|---|---|---|
| Operating margin | 42.8% | 31.5% | 20.3% | 20.3% | 34.6% | 34.3% | |
| Net margin | 23.1% | -19.9% | -12.4% | 2.1% | 18.0% | 20.1% | |
| Return on equity | 4.1% | -3.4% | -2.5% | 0.5% | 4.6% | 5.5% | |
| Return on assets | 2.3% | -1.9% | -1.4% | 0.3% | 2.4% | 2.8% | |
| Return on invested capital | 4.5% | 3.1% | 2.1% | 2.2% | 4.7% | 5.1% | |
| Debt / equity | 0.70 | 0.71 | 0.82 | 0.86 | 0.88 | 0.90 | |
| Net debt / EBITDA | 5.3x | 6.4x | 7.8x | 7.5x | 5.7x | 5.4x | |
| Interest coverage | 2.6x | 1.8x | 1.2x | 1.2x | 2.1x | 2.4x |
Data source: SEC EDGAR, company annual reports. Lines a company does not report are left empty. Free cash flow is operating cash flow minus capital expenditure. Ratios use the same formulas as the EdgeScore check.
For information and education only. Not investment advice. Data may contain errors.